The average life expectancy of someone taking Verzenio isn’t known. (Life expectancy is the length of time that a person is expected to live.)
In clinical trials, researchers didn’t measure life expectancy. Instead, they looked at progression-free survival. This is a period of time during which a person’s cancer doesn’t worsen.
In these trials, people who took Verzenio with an aromatase inhibitor drug, such as anastrozole (Arimidex), had a progression-free survival rate of about 28.2 months. In comparison, people who took a placebo* with an aromatase inhibitor had a progression-free survival rate of about 14.8 months.
If you have additional questions about life expectancy while taking Verzenio, talk with your doctor.
* A placebo is a treatment without an active drug.